Ai Fen

Ai Fen


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

31 July 2019 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
XFX. Fang
X. Fang
CLC.-X. Liu
C.-X. Liu
XZX.-R. Zeng
X.-R. Zeng
XHX.-M. Huang
X.-M. Huang
WCWenli Chen
Wenli Chen
AFAi Fen
Ai Fen

30 April 2026 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
YLYu Li
Yu Li
ZCZhen Chen
Zhen Chen
BCBingxin Cheng
Bingxin Cheng
JLJinglei Li
Jinglei Li
AFAi Fen
Ai Fen
The implantable cardioverter defibrillator (ICD) is an effective therapeutic option for hypertrophic cardiomyopathy (HCM). However, a comprehensive quantit

1 July 2021 in Frontiers in Radiology
Verified
Journal Article
Open access
XLXiang Li
Xiang Li
NLNannan Li
Nannan Li
ZCZhen Chen
Zhen Chen
LYLing Ye
Ling Ye
LZLing Zhang
Ling Zhang
XWXiang Wang
Xiang Wang
Purpose: Computed tomography (CT) characteristics associated with critical outcomes of patients with coronavirus disease 2019 (COVID-19) have been reported. However, CT risk factors for mortality have not been directly reported. We aim to determine the CT-based quantitative predictors for COVID-19 mortality.Methods: In this retrospective study, laboratory-confirmed COVID-19 patients at Wuhan Central Hospital between December 9, 2019, and March 19, 2020, were included. A novel prognostic biomarker, V-HU score, depicting the volume (V) of total pneumonia infection and the average Hounsfield unit (HU) of consolidation areas was automatically quantified from CT by an artificial intelligence (AI) system. Cox proportional hazards models were used to investigate risk factors for mortality.Results: The study included 238 patients (women 136/238, 57%; median age, 65 years, IQR 51–74 years), 126 of whom were survivors. The V-HU score was an independent predictor (hazard ratio [HR] 2.78, 95% confidence interval [CI] 1.50–5.17; p = 0.001) after adjusting for several COVID-19 prognostic indicators significant in univariable analysis. The prognostic performance of the model containing clinical and outpatient laboratory factors was improved by integrating the V-HU score (c-index: 0.695 vs. 0.728; p < 0.001). Older patients (age ≥ 65 years; HR 3.56, 95% CI 1.64–7.71; p < 0.001) and younger patients (age < 65 years; HR 4.60, 95% CI 1.92–10.99; p < 0.001) could be further risk-stratified by the V-HU score.Conclusions: A combination of an increased volume of total pneumonia infection and high HU value of consolidation areas showed a strong correlation to COVID-19 mortality, as determined by AI quantified CT.

Verified
Journal Article
Open access
PDF file
JLJinlei Li
Jinlei Li
AFAi Fen
Ai Fen
YLYu Li
Yu Li
BCBingxin Cheng
Bingxin Cheng
ZCZhen Chen
Zhen Chen
Objective: Although echocardiography is the gold standard for diagnosing left ventricularoutflow tract obstruction (LVOTO) in hypertrophic cardiomyopathy (HCM), relying solely on imaging is insufficient for precise risk stratification, particularly in borderline or atypical patients, and fails to capture systemic pathophysiological alterations. In recent years, novel inflammatory biomarkers derived from routine blood tests have shown sensitivity in capturing micro-inflammatory states; however, their specific roles in the obstructive phenotype of HCM remain unclear. This study aims to screen hematological and cardiac parameters associated with HCM obstruction and to construct an individualized predictive model. Therefore, this study aims to screen hematological and cardiac parameters associated with HCM obstruction and to develop and validate a nomogram for individualized prediction of current LVOTO risk in HCM patients. Methods: A total of 230 HCM patients hospitalized at The Central Hospital of Wuhan from January 2019 to December 2025 were retrospectively enrolled. Based on the left ventricular outflow tract pressure gradient (LVOTPG), they were divided into a non-obstruction group (n = 177) and an obstruction group (n = 53). Least absolute shrinkage and selection operator (LASSO) regression was used to screen feature variables, and multivariate logistic regression analysis was employed to identify independent predictors and construct a nomogram prediction model. The discrimination, calibration, and clinical utility of the model were evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Results: Multivariate logistic regression analysis revealed that a history of alcohol consumption (OR = 3.68, 95% CI: 1.49–9.09), peak LVOTPG (OR = 3.96, 95% CI: 1.42–11.05), maximum ventricular wall thickness (OR = 1.02, 95% CI: 1.00–1.04), peak mitral valve E-wave velocity (OR = 1.02, 95% CI: 1.00–1.04), and neutrophil count (OR = 2.42, 95% CI: 1.13–5.21) were independent predictors of LVOTO in HCM patients. The nomogram model constructed based on these factors achieved area under the curve (AUC) values of 0.810 and 0.850 in the training and validation sets, respectively. The calibration curve demonstrated good agreement between predicted and actual probabilities, and DCA indicated that the model provided clinical net benefit within a threshold probability range of 10% to 30%. Conclusions: A nomogram integrating alcohol consumption history, peak LVOTPG, maximum ventricular wall thickness, peak mitral E-wave velocity, and neutrophil count accurately predicts LVOTO risk in HCM patients (AUC: 0.810–0.850), providing a low-cost tool for early risk stratification. External prospective validation is warranted.

12 June 2026 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
YLYu Li
Yu Li
ZDZiqi Duan
Ziqi Duan
JLJinlei Li
Jinlei Li
BCBingxin Cheng
Bingxin Cheng
AFAi Fen
Ai Fen
ZCZhen Chen
Zhen Chen
Background: The risk of early left ventricular systolic dysfunction progression (ELVSDP) among patients with hypertrophic cardiomyopathy (HCM) is heterogeneous, and accurate short-and medium-term prediction tools are lacking. This study aimed to develop and validate a predictive model for the risk of ELVSDP in HCM patients at 6, 12, and 18 months. Methods: A total of 314 HCM patients without ELVSDP at baseline were included and randomly divided into training and validation sets. LASSO-Cox regression was employed to select variables and identify independent predictors, based on which a nomogram and an interactive dynamic prediction tool were constructed. Model performance was evaluated using the concordance index (C-index), time-dependent receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Risk stratification was assessed using the Kaplan–Meier method. Results: Age [hazard ratio (HR) = 1.17], smoking history (HR = 2.79), B-type natriuretic peptide (BNP) level (HR = 1.002), and left ventricular outflow tract obstruction (HR = 2.24) were independent predictors of ELVSDP. The model demonstrated strong performance in both the training and validation sets. The time-dependent area under the curve (AUC) exceeded 0.88 at 6, 12, and 18 months, with C-indices of 0.94 and 0.93, respectively. Bootstrap validation confirmed model stability. Calibration curves showed good agreement between predicted and observed outcomes, and DCA indicated a net clinical benefit. The incidence of ELVSDP was significantly higher in the high-risk group compared to the low-risk group ( P < 0.0001). Conclusion: The nomogram developed in this study accurately predicts short-term ELVSDP risk in HCM patients, facilitating early risk stratification and individualized management. Clinical Trial Registration: This study was registered at the Chinese Clinical Trial Registry http://www.chictr.org.cn/ , registration number ChiCTR2500106648 [Registration Date: 2025-07-28].